# Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

> **NCT02412449** · PHASE1 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AKB-6548 tablet, reference formulation given in the fasted state
- **DRUG:** AKB-6548 tablet, test formulation given in the fasted state.
- **DRUG:** AKB-6548 tablet, test formulation given in the fed state

## Key facts

- **NCT ID:** NCT02412449
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02412449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02412449, "Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02412449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*